FORA Capital’s Moderna MRNA Stock Holding History

FORA Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,760	Closed	-$462K	–	540
2025 Q4	$462K	Buy	+25,760	New	+$700K	0.06%	310
2025 Q3	–	Sell	-58,077	Closed	-$1.6M	–	612
2025 Q2	$1.6M	Sell	58,077 -38,995	-40%	-$1.03M	0.18%	153
2025 Q1	$2.75M	Buy	97,072 +23,344	+32%	+$828K	0.28%	118
2024 Q4	$3.07M	Buy	+73,728	New	+$3.52M	0.35%	90
2023 Q1	–	Sell	-41,140	Closed	-$7.39M	–	634
2022 Q4	$7.39M	Buy	+41,140	New	+$6.73M	1.19%	10
2022 Q2	–	Sell	-21,002	Closed	-$3.67M	–	591
2022 Q1	$3.67M	Buy	+21,002	New	+$3.54M	0.66%	27
2021 Q4	–	Sell	-8,007	Closed	-$3.08M	–	404
2021 Q3	$3.08M	Buy	+8,007	New	+$2.95M	0.78%	29
2021 Q2	–	Sell	-10,699	Closed	-$1.4M	–	1049
2021 Q1	$1.4M	Sell	10,699 -28,376	-73%	-$4.11M	0.46%	49
2020 Q4	$4.08M	Buy	+39,075	New	+$3.95M	0.62%	29
2020 Q2	–	Sell	-47,533	Closed	-$1.42M	–	1152
2020 Q1	$1.42M	Buy	+47,533	New	+$1.09M	0.31%	77

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FORA Capital's MRNA Position: Q1 2026 in Review

FORA Capital sold out of Moderna (MRNA) in Q1 2026, closing a stake of 25,760 shares — an estimated $462K sold.

FORA Capital first reported a position in MRNA in Q1 2020 and held it in 10 quarters. The position peaked at $7.39M in Q4 2022. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

FORA Capital reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
FORA Capital sold 25,760 Moderna shares in Q1 2026, an estimated $462K.
FORA Capital first reported a position in Moderna in Q1 2020 and held it in 10 quarters.
FORA Capital's Moderna position peaked at $7.39M in Q4 2022.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.